Free Trial

Anixa Biosciences Q1 2024 Earnings Report

Anixa Biosciences logo
$2.41 -0.17 (-6.59%)
As of 01/17/2025 04:00 PM Eastern

Anixa Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Anixa Biosciences Earnings Headlines

Anixa Biosciences (ANIX) Projected to Post Earnings on Tuesday
Stunning Trump Exec Order Leaked
Most people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... This could be the most important building in America.
Anixa Biosciences Leads 3 Promising Penny Stocks On US Exchanges
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat